UroGen Pharma

Yahoo Finance • last year

Retrospective Study Finds JELMYTO® Use Effective Following Partial Ablation or Biopsy in Larger Volume Low-Grade Upper Tract Urothelial Tumors that Impede Kidney Preservation

PRINCETON, N.J., July 10, 2023--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today highlights the result... Full story

Yahoo Finance • last year

Retrospective Study Reveals Lower Stricture Rate and Comparable Oncological Outcomes with Antegrade Administration of JELMYTO® Versus Retrograde Administration

PRINCETON, N.J., June 20, 2023--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today highlights the result... Full story

Yahoo Finance • 2 years ago

UroGen Pharma Ltd. (NASDAQ:URGN) Q1 2023 Earnings Call Transcript

UroGen Pharma Ltd. (NASDAQ:URGN) Q1 2023 Earnings Call Transcript May 11, 2023 UroGen Pharma Ltd. beats earnings expectations. Reported EPS is $-1.3, expectations were $-1.33. Operator: Good morning, ladies and gentlemen. Thank you for s... Full story

Yahoo Finance • 2 years ago

UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

PRINCETON, N.J., December 09, 2022--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN) a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the gran... Full story

Yahoo Finance • 3 years ago

Phathom Pharmaceuticals Reports First Quarter 2022 Results and Provides Recent Clinical, Regulatory, and Business Updates

U.S. Food and Drug Administration (FDA) approval received for VOQUEZNA™ TRIPLE PAK™ (vonoprazan, amoxicillin, clarithromycin) and VOQUEZNA™ DUAL PAK™ (vonoprazan, amoxicillin) for treatment of H. pylori infection in adults Up to $260 mill... Full story